JP2024523453A5 - - Google Patents

Info

Publication number
JP2024523453A5
JP2024523453A5 JP2023578817A JP2023578817A JP2024523453A5 JP 2024523453 A5 JP2024523453 A5 JP 2024523453A5 JP 2023578817 A JP2023578817 A JP 2023578817A JP 2023578817 A JP2023578817 A JP 2023578817A JP 2024523453 A5 JP2024523453 A5 JP 2024523453A5
Authority
JP
Japan
Prior art keywords
alkyldiyl
peg
pep
heterocyclyldiyl
immunocomplex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523453A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034865 external-priority patent/WO2022272039A1/en
Publication of JP2024523453A publication Critical patent/JP2024523453A/ja
Publication of JP2024523453A5 publication Critical patent/JP2024523453A5/ja
Pending legal-status Critical Current

Links

JP2023578817A 2021-06-25 2022-06-24 ビス-ベンゾイミダゾールstingアゴニスト免疫複合体及びその使用 Pending JP2024523453A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163215100P 2021-06-25 2021-06-25
US63/215,100 2021-06-25
PCT/US2022/034865 WO2022272039A1 (en) 2021-06-25 2022-06-24 Bis-benzimidazole sting agonist immunoconjugates, and uses thereof

Publications (2)

Publication Number Publication Date
JP2024523453A JP2024523453A (ja) 2024-06-28
JP2024523453A5 true JP2024523453A5 (cg-RX-API-DMAC7.html) 2025-06-16

Family

ID=82850579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578817A Pending JP2024523453A (ja) 2021-06-25 2022-06-24 ビス-ベンゾイミダゾールstingアゴニスト免疫複合体及びその使用

Country Status (9)

Country Link
US (1) US20250057967A2 (cg-RX-API-DMAC7.html)
EP (1) EP4359007A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024523453A (cg-RX-API-DMAC7.html)
KR (1) KR20240027018A (cg-RX-API-DMAC7.html)
CN (1) CN117794583A (cg-RX-API-DMAC7.html)
AU (1) AU2022300383A1 (cg-RX-API-DMAC7.html)
CA (1) CA3222082A1 (cg-RX-API-DMAC7.html)
IL (1) IL309278A (cg-RX-API-DMAC7.html)
WO (1) WO2022272039A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024137619A1 (en) * 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
WO2024174863A1 (zh) * 2023-02-22 2024-08-29 深圳众格生物科技有限公司 Sting激动剂及其制备方法和医药用途
AU2024315750A1 (en) 2023-07-31 2026-03-05 Sutro Biopharma, Inc. Sting agonist compounds and conjugates
CN117771206B (zh) * 2023-08-02 2024-05-28 首都医科大学附属北京儿童医院 Sting激动剂仿生纳米递送系统及其制备方法和应用
WO2025233679A1 (en) * 2024-05-08 2025-11-13 Ligachem Biosciences Inc. Compositions and methods related to a combination therapy of sting agonists and antibody drug conjugates
TW202604486A (zh) * 2024-05-08 2026-02-01 韓商瑞嘉化學生物科學股份有限公司 與sting促效劑及免疫檢查點抑制劑之組合療法相關之組合物及方法
TW202613130A (zh) 2024-05-30 2026-04-01 日商安斯泰來製藥股份有限公司 Sting促效劑免疫刺激性抗體藥物結合物
WO2026055185A1 (en) * 2024-09-04 2026-03-12 Bolt Biotherapeutics, Inc. Sting agonist immunoconjugates and uses thereof
WO2026078593A1 (en) 2024-10-08 2026-04-16 Sun Pharma Advanced Research Company Limited Sting agonists and antibody drug conjugates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201900628RA (en) * 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
AR113224A1 (es) * 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
AU2018344902B2 (en) * 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
US11377440B2 (en) * 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
CN118846110A (zh) * 2018-09-06 2024-10-29 第一三共株式会社 抗体药物偶联物
CN113348181A (zh) * 2018-10-31 2021-09-03 诺华股份有限公司 包含sting激动剂的dc-sign抗体缀合物
JP2022529183A (ja) * 2019-04-17 2022-06-17 アヴィディア テクノロジーズ, インコーポレイテッド リガンド提示および/または薬物送達のためのスターポリマーを製造する組成物および方法
TWI925817B (zh) * 2019-05-10 2026-05-21 日商武田藥品工業股份有限公司 抗體藥物結合物
JP2022537158A (ja) * 2019-06-13 2022-08-24 ボルト バイオセラピューティクス、インコーポレーテッド アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用
US11033635B2 (en) * 2019-07-19 2021-06-15 Immunesensor Therapeutics, Inc. Antibody-STING agonist conjugates and their use in immunotherapy
CN116196435B (zh) * 2020-04-02 2025-12-02 梅尔莎纳医疗公司 包含sting激动剂的抗体药物缀合物

Similar Documents

Publication Publication Date Title
JP2023524271A5 (cg-RX-API-DMAC7.html)
JP2022537158A5 (cg-RX-API-DMAC7.html)
JP2022553702A5 (cg-RX-API-DMAC7.html)
JP2022549510A5 (cg-RX-API-DMAC7.html)
JP2023553421A5 (ja) 抗cea免疫複合体、及びその使用
TWI790996B (zh) 用於製備聚乙二醇化的藥物-連接劑及其中間體之方法
FI3958977T3 (fi) Kamptotesiinijohdannaisia
ES2755101T3 (es) Nuevos compuestos y conjugados de criptoficina, su preparación y su uso terapéutico
RU2015156499A (ru) Конъюгаты антитела с лекарственным средством
HRP20230275T1 (hr) Antitijelo-lijek konjugati koji sadrže derivate ekteinascidina
JP2022546110A5 (cg-RX-API-DMAC7.html)
IL276514B1 (en) Glypican 3 antibodies and conjugates thereof
JP2023552792A5 (cg-RX-API-DMAC7.html)
JP2023552791A5 (cg-RX-API-DMAC7.html)
JP2012522512A5 (cg-RX-API-DMAC7.html)
JP2012522513A5 (cg-RX-API-DMAC7.html)
JP2023070678A5 (cg-RX-API-DMAC7.html)
JP2022512830A5 (cg-RX-API-DMAC7.html)
JP2015524796A5 (ja) 細胞毒性剤と細胞結合受容体との共役体
JP2024533356A5 (cg-RX-API-DMAC7.html)
JP2024501453A5 (cg-RX-API-DMAC7.html)
JP2023552790A5 (cg-RX-API-DMAC7.html)
JP2024511088A5 (cg-RX-API-DMAC7.html)
IL273387B1 (en) Thylanstatin analogs
JP2022554094A5 (cg-RX-API-DMAC7.html)